Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
Frederick Berro RiveraGrace Nooriza O LumbangDanielle Rose Magno GaidLinnaeus Louisse A CruzJohn Vincent MagalongNathan Ross B BantayanKyla M Lara-BreitingerMartha GulatiGeorge L BakrisPublished in: Diabetes, obesity & metabolism (2024)
Patients on GLP-1RA experienced modest SBP lowering compared with placebo. This observed effect was associated with weight/body mass index reduction and better glycaemic control, which suggests that BP-lowering is an indirect effect of GLP-1RA and unlikely to be responsible for the benefits.
Keyphrases
- body mass index
- blood pressure
- end stage renal disease
- rheumatoid arthritis
- ejection fraction
- newly diagnosed
- weight gain
- type diabetes
- physical activity
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- weight loss
- clinical trial
- patient reported outcomes
- metabolic syndrome
- systemic lupus erythematosus
- skeletal muscle
- blood glucose